Skip to main content

Month: May 2021

Tulikivi is revising its guidance for 2021 upward: Net sales are expected to be between EUR 31 and 33 million, and the comparable operating profit is expected to improve substantially

Tulikivi is revising its guidance for 2021 upward: Net sales are expected to be between EUR 31 and 33 million, and the comparable operating profit is expected to improve substantially Previous guidance for 2021 (published on 5 March 2021): Net sales are expected to increase and the comparable operating profit is expected to improve. Tulikivi is now revising its earlier estimate of the 2021 net sales and comparable operating profit upward. The net sales in 2020 were EUR 29.2 million and the comparable operating profit was EUR 1.2 million. According to the new estimate, net sales in 2021 are expected to be EUR 31 to 33 million and the comparable operating profit is expected to improve substantially.  The improved outlook is based on a strong order intake from Finland and abroad during the early part of the year. TULIKIVI CORPORATION Board...

Continue reading

CSPi to Announce Fiscal Second Quarter Financial Results on Tuesday May 11th

LOWELL, Mass., May 05, 2021 (GLOBE NEWSWIRE) — CSPi (NASDAQ: CSPI), a provider of security and packet capture products, managed IT and professional services and technology solutions, announced that it will issue its fiscal second quarter financial results before the open of the market on Tuesday, May 11, 2021. CSPi President and Chief Executive Officer Victor Dellovo and Chief Financial Officer Gary W. Levine will host a conference call at 10:00 a.m. ET that day to review the financial results and provide a business update. To listen to a live webcast of the call, please visit the “Investor Relations” section of the Company’s website at http://www.cspi.com/. Individuals also may listen to the call via telephone, by dialing 877-876-9173, 785-424-1667 and use the Conference ID: CSPQ221 when greeted by the live operator. A replay...

Continue reading

Information relating to the total number total of voting rights and of shares as of April 30, 2021

Name of issuer: NATIXIS S.A. joint stock company with a share capital of 5,052,644,851.20 eurosRegistered under the number B 542 044 524 RCS ParisRegistered Office: 30 avenue Pierre Mendès-France – 75013 ParisInformation relating to the total number total of voting rights and of shares pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the French Financial Markets Supervision Authority (AMF) General Regulations.DateNumber of shares composing current share capital Total number of voting rightsApril 30, 20213,157,903,032Gross total: 3,157,903,032 Net total*: 3,155,441,451* Net total: total number of voting rights attached to the total number of shares – shares without voting rights (treasury stock, etc.) The €5,052,644,851.20 share capital has been registered by a decision of...

Continue reading

Gold’n Futures Engages Independent Trading Group as Market Maker

VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) — GOLD’N FUTURES MINERAL CORP. (CSE: FUTR) (FSE: G6M), (OTC: GFTRF) (the “Company” or “Gold’n Futures”) announces it has engaged the services of Independent Trading Group (“ITG”) to provide market-making services. ITG will trade shares of the Company on the Canadian Securities Exchange with the goal of maintaining a reasonable trading market and improving the liquidity of the Company’s common shares. Under the agreement, ITG will receive compensation of C$6,000 per month, payable monthly in advance. The agreement is for an initial term of three months, ending on July 31, 2021 and will renew for additional one month terms unless terminated. The agreement may be terminated by either party with 30 days’ notice. There are no performance factors...

Continue reading

Adoption of resolutions of shareholders

The Management Board of AS Merko Ehitus, registry code 11520257, seated at Järvevana tee 9G, Tallinn, 11314 (hereinafter – “Company”), proposed to the shareholders to adopt resolutions without convening a general meeting. The notice of adoption of resolutions without convening a general meeting was published on 7 April 2021 in the stock exchange information system (https://www.nasdaqbaltic.com/statistics/et/news/319655) and on the Company’s homepage (https://group.merko.ee/en/general-meeting-of-shareholders/agm-2021/), as well as in the 9 April 2021 issue of newspaper “Postimees”. 20 shareholders of the Company cast their votes by the deadline of 5 May 2021 9:00 AM Estonian time. Their votes represent 12,855,401 votes out of the 17,700,000 shares represented by votes of the Company, i.e. 72.63% of all the shares represented by votes. If...

Continue reading

ContextVision Annual General Meeting 2021

On the 5th of May 2021, ContextVision held its ordinary Shareholders’ Annual General Meeting in Stockholm. Due to the extraordinary situation that prevails as a result of the covid-19 pandemic the Annual General Meeting was conducted by advance voting (postal voting) with the support of temporary statutory rules (Sections 20 – 22 of the Act (2020: 198) on temporary exemptions to facilitate the conduct of general and association meetings). There was no opportunity to attend the Annual General Meeting in person or by proxy. Information on the resolutions passed at the meeting was disclosed on May 5, 2021, as soon as the outcome of the postal voting had been finally confirmed. Major items approved by the Annual General Meeting include:The annual financial report regarding 2020 was approved by the AGM. Disposition of financial...

Continue reading

22nd Century Group Installs State-of-the-Art Nicotine Testing Equipment to Enhance VLN® Production

Investment in New Lab Capabilities Will Reduce Testing Costs by 90% and Improve Turnaround Time from Weeks to Hours BUFFALO, N.Y., May 05, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, announced today that it is advancing and expanding capabilities in its in-house laboratory, located in its cigarette manufacturing facility in Mocksville, North Carolina, for testing of its VLN® reduced nicotine content (RNC) tobacco and cigarettes. The Company estimates that its cost per VLN® sample will improve by more than 90% and the lead time for key data will take less than a day compared to using a third-party testing service that can take weeks. “This is an important investment and...

Continue reading

Resverlogix Announces US$6 Million Debenture Financing

CALGARY, Alberta, May 05, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”) which provides for Hepalink to purchase 10% secured convertible debentures of the Company in the aggregate principal amount of US$6 million (the “Debentures”) for a purchase price equal to the principal amount of the Debentures (the “Debenture Financing”). The Debentures will bear interest at a rate of 10% per annum and mature one year from the first closing date of the Debenture Financing. Hepalink may elect to convert the principal amount of the Debentures and accrued and unpaid interest thereon into common shares of the Company at a conversion price equal to...

Continue reading

Willis Towers Watson launches working group to explore “new breed” of investment manager

ARLINGTON, Va., May 05, 2021 (GLOBE NEWSWIRE) — Willis Towers Watson has launched a dedicated working group that brings together expertise from both its public and private equity investment research teams, to assess the potential for what it calls a “new breed” of investment management firm that invests across the entire equity spectrum. The working group, which was established in March 2021, will actively evaluate opportunities in the public/private equity space. In its recent paper, titled “Institutional allocation to private equity,” Willis Towers Watson has shown that while there are strong structural tailwinds to support the continuing rise of private equity in institutional portfolios, the private equity industry itself needs to evolve more actively the way in which it structures its investments in order to fully capture...

Continue reading

Relevium Provides Update on the Exclusive Supply of Medical Examination Gloves

MONTREAL, May 05, 2021 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), whose primary mandate is to focus on international procurement, logistics, and delivery of Personal Protective Equipment (“PPE) and wellness products, is pleased to provide an update on the performance of the exclusivity contract to supply medical examination gloves for North America. On March 11, 2021 (see Press Release), Relevium announced the procurement and subsequent delivery of the first production batch of Personal Protective Equipment (“PPE”) from a Supply Agreement entered into during the last quarter of 2020 with 24 Clean Energy (the “Supplier”), a manufacturer and distributor of high-end medical grade nitrile gloves. The Company also announced it had obtained the “exclusive”...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.